Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study

被引：0
|
作者：
Kilari, D. [1 ]
Szabo, A. [2 ,3 ]
Bilen, M. A. [4 ]
Ged, Y. [5 ]
Maughan, B. L. [6 ]
Hwang, C. [7 ]
McManus, H. [8 ]
Barata, P. M. Coelho [9 ]
Desai, A. [10 ]
Zakharia, Y. [11 ]
Emamekhoo, H. [12 ]
Tripathi, A. [13 ]
Rose, T. [14 ]
Ghatalia, P. [15 ]
Reimers, M. A. [16 ]
Heath, E. [17 ]
King, J. M. [18 ]
Rini, B. I. [19 ]
Brugarolas, J. [20 ]
Mckay, R. R. [21 ]
机构：
[1] Med Coll Wisconsin, Dept Med, Milwaukee, WI 53226 USA
[2] Froedtert Hosp, Med, Milwaukee, WI USA
[3] Med Coll Wisconsin, Milwaukee, WI 53226 USA
[4] Emory Univ, Dept Oncol, Winship Canc Inst, Atlanta, GA 30322 USA
[5] Johns Hopkins Univ Hosp, Dept Oncol, Baltimore, MD USA
[6] Univ Utah Hlth, Div Med Oncol, Dept Internal Med, Huntsman Canc Inst, Salt Lake City, UT USA
[7] Henry Ford Hlth, Internal Med Hematol Oncol, Henry Ford Canc Inst, Detroit, MI USA
[8] Duke Univ, Med Ctr, Med, Durham, NC USA
[9] Univ Hosp Seidman Canc Ctr, Dept Internal Med, Cleveland, OH USA
[10] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA
[11] Univ Iowa Hosp & Clin, Dept Internal Med, Iowa City, IA 52242 USA
[12] UW Carbone Canc Ctr, Hematol Oncol, Madison, WI USA
[13] City Hope Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA USA
[14] UNC Lineberger Comprehens Canc Ctr, Med, Chapel Hill, NC USA
[15] Fox Chase Canc Ctr Main Campus, 1Med Oncol, Philadelphia, PA USA
[16] Washington Univ, Sch Med, Dept Internal Med, St Louis, MO 63110 USA
[17] Karmanos Canc Inst, Oncol, Detroit, MI USA
[18] Indiana Univ, Simon Canc Ctr, Med Oncol, Indianapolis, IN 46204 USA
[19] Vanderbilt Ingram Canc Ctr, Dept Oncol, Nashville, TN USA
[20] UT Southwestern Med Ctr, Dallas, TX USA
[21] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.1802
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1709P
引用
收藏
页码：S1024 / S1025
页数：2
相关论文
共 50 条
  • [1] Outcomes with novel combinations in non-clear cell renal cell carcinoma(nccRCC): ORACLE study.
    Kilari, Deepak
    Szabo, Aniko
    Ghatalia, Pooja
    Rose, Tracy L.
    Weise, Nicole
    Tucker, Matthew D.
    Nelson, Ariel Ann
    Dong, Huaying
    Hester, Danubia
    Acharya, Luna
    Jain, Rohit K.
    Maughan, Benjamin L.
    Alva, Ajjai Shivaram
    Tripathi, Abhishek
    Basu, Arnab
    Koshkin, Vadim S.
    Emamekhoo, Hamid
    Davis, Nancy B.
    Desai, Arpita
    McKay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Outcomes with novel combinations in nonclear cell renal cell carcinoma (nccRCC): ORACLE study.
    Kilari, Deepak
    Szabo, Aniko
    Ghatalia, Pooja
    Rose, Tracy L.
    Dong, Huaying
    Weise, Nicole
    Zhuang, Tony Z.
    Alloghbi, Abdurahman
    Jain, Rohit K.
    Alva, Ajjai Shivaram
    Tripathi, Abhishek
    Basu, Arnab
    Davis, Nancy B.
    Brundage, James
    Emamekhoo, Hamid
    Zakharia, Yousef
    Koshkin, Vadim S.
    Bilen, Mehmet Asim
    Heath, Elisabeth I.
    McKay, Rana R.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Non-clear cell renal cell carcinoma (nccRCC): A Brazilian experience.
    Yamamura, Rosely
    Rinck, Jose A.
    Fonseca Jesus, Victor Hugo
    Tavares, Monique Celeste
    de Castro Larclprete, Ana Luisa
    Iennaco, Pietro Schettlni
    Freitas, Heleno C.
    Cunha, Isabela Warneck
    Fanelli, Marcello Ferretti
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [4] Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC).
    Mckay, Rana R.
    McGregor, Bradley Alexander
    Gray, Kathryn
    Steinharter, John A.
    Walsh, Meghara K.
    Braun, David A.
    Flaifel, Abdallah
    VanAllen, Eliezer
    Wei, Xiao X.
    Signoretti, Sabina
    Harshman, Lauren Christine
    Vaishampayan, Ulka N.
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] Non-clear cell renal cell carcinoma
    Ahrens, Marit
    Bergmann, Lothar
    UROLOGIE, 2024, 63 (12): : 1240 - 1245
  • [6] Non-Clear Cell Renal Cell Carcinoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (01) : 8 - 10
  • [7] A phase II study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma (nccRCC)
    Hutson, Thomas E.
    Michaelson, M. Dror
    Kuzel, Timothy M.
    Agarwal, Neeraj
    Molina, Ana M.
    Hsieh, James J.
    Vaishampayan, Ulka N.
    Xie, Sharon
    Bapat, Urmi
    Jain, Rohit K.
    Fishman, Mayer N.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [8] Cabozantinib (Cabo) in advanced non-clear cell renal cell carcinoma (nccRCC): A retrospective multicenter analysis.
    Chanza, Nieves Martinez
    Bosse, Dominick
    Bilen, Mehmet Asim
    Geynisman, Daniel M.
    Balakrishnan, Archana
    Jain, Rohit K.
    Bowman, I. Alex
    Zakharia, Yousef
    Narayan, Vivek
    Beuselinck, Benoit
    Agarwal, Neeraj
    McKay, Rana R.
    Hsu, Joann
    Shah, Sumit
    Tripathi, Abhishek
    Lam, Elaine Tat
    Rose, Tracy Lynn
    Carneiro, Benedito A.
    Vogelzang, Nicholas J.
    Harshman, Lauren Christine
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Effectiveness of first-line therapy in patients with advanced non-clear renal cell carcinoma (nccRCC).
    Laramee, Sophie
    Ghosh, Sunita
    Kollmannsberger, Christian K.
    Hansen, Aaron Richard
    Wood, Lori
    Soulieres, Denis
    Canil, Christina M.
    Saleh, Ramy
    Castonguay, Vincent
    Bjarnason, Georg A.
    Basappa, Naveen S.
    Breau, Rodney H.
    Heng, Daniel Yick Chin
    Pouliot, Frederic
    Kapoor, Anil
    Lalani, Aly-Khan A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [10] Therapeutic approaches in clear cell and non-clear cell renal cell carcinoma
    Vermassen, T.
    De Meulenaere, A.
    Van de Walle, M.
    Rottey, Sylvie
    ACTA CLINICA BELGICA, 2017, 72 (01) : 12 - 18
12345